Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 4Triple Negative Breast Neoplasms 2Ovarian Neoplasms 2Neoplasm Metastasis 2Advanced Nonhematologic Malignancies 2Waldenstrom Macroglobulinemia 1Thyroid Neoplasms 1Thyroid Carcinoma, Anaplastic 1Somatostatinoma 1Recurrent Malignant Solid Neoplasm 1Recurrent Lung Squamous Cell Carcinoma 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Non-hematologic Malignancy 1Neoplasms 1Multiple Myeloma 1Metastatic Castration-Resistant Prostate Cancer 1Lung Neoplasms 1Hematologic Neoplasms 1Fibrolamellar hepatocellular carcinoma 1Fallopian Tube Neoplasms 1Endometrial Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Merkel Cell 1Burkitt Lymphoma 1Advanced Solid Tumors 1Advanced Solid Tumor 1Advanced Solid Malignancies 1Adenoma, Islet Cell 1

Interventions

Capecitabine 3Trastuzumab 2Temozolomide 2Sunitinib 2Octreotide 2Leucovorin 2Everolimus 2Bevacizumab 2vatalanib 1tipifarnib 1temsirolimus 1sapanisertib 1regorafenib 1pentetreotide 1pazopanib 1palbociclib 1motesanib diphosphate 1lutetium Lu 177 dotatate 1gallium Ga 68 dotatate 1cixutumumab 1batifiban 1aflibercept 1Thalidomide 1Streptozocin 1Sorafenib 1Sirolimus 1Salts 1Oxaliplatin 1Melphalan 1Magnetic Resonance Spectroscopy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Somatostatinoma × sapanisertib × Clear all
NCT02893930 2023-10-17

Sapanisertib in Treating Patients With Metastatic or Refractory Pancreatic Neuroendocrine Tumor That Cannot Be Removed by Surgery

National Cancer Institute (NCI)

Phase 2 Completed
13 enrolled 9 charts

Somatostatinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡